>The Complement System, An Innate Immunity Station
The Complement System occupies a unique position among early cellular sensors, acting directly on the surface of triggering cells or substances to coordinate downstream cellular humoral immune responses. This makes this system a critical part of the immune cascade, contributing to both innate immune responses, including:
As a global regulator of immunity and tissue homeostasis, the Complement System has become an interesting, yet complex pharmacological target, contributing a network that contributes to pathogenesis in various inflammatory and neurodegenerative diseases, as well as, cancers.
Overall, the Complement-targeted therapies has been a very active field in recent years. Potent complement inhibitors are now available and increasingly used in approved and off-label indications that demonstrate the therapeutic potential of complement control.
Complement activation is implicated in numerous diseases
Anti-complement drugs currently in clinical development
A better understanding of the complement's structure, function, and biological role will support our complement-based understanding to contribute to treating inflammation, neurodegenerative diseases, and cancers. Complement-targeted drugs that intervene at the signaling cascade level can help to better tailor therapeutic strategies and allow such strategies to be applied to a wider range of indications. To assist with research h into the Complement system, ACROBiosystems has developed a series of recombinant complement proteins expressed by HEK293 Cells, including C2, C3, C5, C5a and complement factor D (CFD).
Comprehensive catalog of Complement products are available
High purity and structural homogeneity verified by SDS-PAGE and SEC-MALS
Native conformation, various species, free protocols available
High biological activity verified by ELISA and cell-based assay
|Molecule||Cat. No.||Species||Product Description||Preorder/Order|
The purity of Human Complement C5a, Fc Tag (Cat. No. C5A-H525a) is more than 90% and the molecular weight of this protein is around 80-90 kDa verified by SEC-MALS.
The purity of Cynomolgus Complement C3, His Tag (Cat. No. CO3-C52H5) is more than 95% and the molecular weight of this protein is around 168-205 kDa verified by SEC-MALS.
Immobilized Human Complement C5, His Tag (Cat. No. CO5-H52Ha) at 2 μg/mL (100 μL/well) can bind Eculizumab Biosimilar with a linear range of 0.1-4 ng/mL (Routinely tested).
Immobilized Human Complement C5a, His Tag (Cat. No. C5A-H51H9) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Human C5a Human Antibody, Human IgG1 with a linear range of 0.1-4 ng/ml (QC tested).
Human Complement C5a, Tag Free (Cat. No. C5A-H5116) induce N-acetyl-β-D-glucosaminidase release from differentiated U937 cells. The ED50 for this effect is 0.215-0.323 μg/mL (Routinely tested).
1. King B C, Blom A M. Intracellular complement: Evidence, definitions, controversies, and solutions[J]. Immunological Reviews, 2023, 313(1): 104-119.
2. Zelek W M, Xie L, Morgan B P, et al. Compendium of current complement therapeutics[J]. Molecular immunology, 2019, 114: 341-352.
3. Lubbers R, Van Essen M F, Van Kooten C, et al. Production of complement components by cells of the immune system[J]. Clinical & Experimental Immunology, 2017, 188(2): 183-194.
4. Ricklin D, Lambris J D. New milestones ahead in complement-targeted therapy[C]//Seminars in immunology. Academic Press, 2016, 28(3): 208-222.
This web search service is supported by Google Inc.